JAZZ Articles, Jazz Pharmaceuticals plc - From 02/14/24

"Tell me and I forget, teach me and I may remember, involve me and I learn." Benjamin Franklin When it comes to the cannabis industry, one of the ...

Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royal...

An Australian, vertically integrated plant-based medicine company, Cannatrek, will collaborate with a Japanese University to empower research on m...

The negative sentiment observed in the stock market at the beginning of the year appears to persist, with index futures pointing to a lower opening...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selecti...

Japan’s Parliament passed a bill Wednesday legalizing medical products derived from cannabis. The news comes some three weeks after the ...

Around 8% of Australians are using medical marijuana either occasionally or regularly, according to a recent survey of 1,000 participants cond...

Medical Cannabis-Based Epidiolex Advances Through Japan's Legislature Earlier this week, Japanese policymakers gave the green light to a m...

Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In...

Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confi...